The oligonucleotide synthesis services at Aurigene is supported by a 1000 sq.ft state-of-the-art lab facility equipped with humidity and endotoxin control. A team of scientists with expertise in various oligonucleotide modalities is available. Our expertise makes fully functionalized oligo and incorporate custom phosphoramidites and conjugates at internal and terminal positions by means of phosphoramidite chemistry or via post-synthetic conjugation strategy. Along with oligonucleotide, we have expert team for in-house synthesis of customized phosphoramidites and conjugates. We make oligos more versatile torough modification and conjugation complex conjugation using click chemistry, amide coupling, thiol exchange and Thiol-ene click reaction.
We make oligos from 3-60 mer length in 50 nmole to 1g scale. This includes hybrid oligos with modifications such as, Sugar (LNA, ribose and 2’-deoxyribose), Base (7-deaza guanosine, C-Nucleosides and abasic and epigenetic), Backbone (PO, PS and PMe), other reactive Functional groups (5’/3’-Thiol, 5’/3’-C6-Amine, 5’/3’-Azide, 5’/3’-Alkyne/BCN/DBCO), and Fluorophores (Alexa, Cy5, Cy3, FAM). Internal modification with the choice of functional group can be customized as per the request.
Oligo equipments at Aurigene: K and A H-16 and H8 automated DNA/RNA synthesizer Shimadzu preparative RP-HPLC AKTA pure 25M FPLC Ion-exchange purification system Sartoflow smart TFF system for concentration and desalting Martin Christ LSC plus Lyophilizer with lyocube, benchtop tray lyophilizer Dedicated Agilent LC-MS for oligonucleotide analysis (up to 100K da) Implen N60 nano spectrophotometer
Synthesis and Purification
- Scale: 1-250 µmol (1-1000 mg)
- 16x1 µmol, 8x40 µmol, 1x250 µmol
- Size: 3 to 60-mer
- 2’-F, 2’-OMe, 2’-O-MOE, LNA and all standard modifications
- Post-synthetic conjugation of Lipids, Peptides, GalNAc, Antibodies, and Chelators at 3’/5’-end of desired oligo.
- Duplexing of antisense and sense strand with >95% purity
- Anion/ Cation exchange purification
- Reverse phase HPLC
- Size exclusion for duplex analysis
- Desalting
Analysis
- UV quantification
- Purity and identity analysis using LC-MS (TOF) and mass deconvolution
- HPLC with different mobile and stationary phase for purity assessment
Biology
- In vitro IC50, Kd and binding assessment and in vivo activities evaluation with wide range of cells. Efficacy experiment in oncology and inflammation model
- Toxicology studies with ASO.
Conjugation
- Acid-amine coupling using direct acid or through NHS chemistry
- Alkyne-azide coupling with/without copper
- S-S and C-S bond formation by disulfide exchange or thiol-ene click
Why Aurigene Oligonucleotide Synthesis Services?
Complex conjugation using click chemistry, amide coupling and thiol mediated C-S & S-S bond
Ion exchange and reverse phase HPLC
Expertise in nucleoside, sugar modifications, base modifications
State-of-the-art drug discovery facility using oligonucleotide modality
CADD Optimization
Synthesis between 3-60-mer oligonucleotide
In-house custom phosphoramidite synthesis
Integrated Services
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Oligo
Connect with our scientific experts for your drug discovery, development, and manufacturing needs
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
Learning Resources
Oligonucleotide as a novel class of therapeutic modality
Oligonucleotides as a therapeutic class is a revolutionary approach to discover new and important therapeutic agents for treating human diseases. RNA-based intervention at times works in cases where other modalities do not work. For example, it may help in treating inborn errors in metabolism, genetic disorders and rareOligonucleotide therapeutics is the use of c...
Read More
HPAPI Molecule from Development to Market
The global Highly Potent Active Pharmaceutical Ingredients (HPAPI) market is expected to reach USD 26.84 Billion by 2023 from USD 17.72 Billion in 2018, at a CAGR 8.7%....
Read More
cGMP Development and Manufacturing Services
Aurigene Pharmaceutical Services has a legacy of +20 years in developing and manufacturing compounds under cGMP. Our manufacturing plants are spread across 3 continents with facilities in India, UK, and Mexico. ...
Read More
Developing a methodology for In situ perfusion based combined tissue distribution and toxicity evaluation study
Challenges: Several repeated in house validation studies were performed to optimize the suitable perfusate (liquid medium intended to pass through the heart), perfusate volume and perfusion rate to ensure complete perfusion of animal subjects (parameters weren’t adjustable) Challenges were encountered in adjusting the perfusion volume and rate vis-à-vis ensuri...
Read More
Synthesis of 2-hydroxy-3-alkyl-2-phenyl-2,3- dihydroquinazolin-4(1H)-one via molybdenum hexacarbonyl mediated CO gas- and ligand free carbonylative reactions
2016
Carbon monoxide gas and ligand-free conditions were developed for the synthesis of 2-hydroxy-3-alkyl-2-phenyl-2,3-dihydroquinazolin4(1H)-one via catalytic carbonylation with molybdenum hexacarbonyl as an efficient carbonylating agent for the three-component reaction of isatoic anhydride, amine, iodobenzene. Mo(CO)6 is a solid carbon monoxide source. The quinazoli...
Read More-
Development and assessment of a Bcs class II - SGLT2 (Sodium Glucose Cotransporter 2) inhibitor drug in the form of solid lipid Nanoparticles by selecting different lipids, co-surfactants, and manufacturing techniques
Drug Delivery System (DDS) has been used successfully in the past few decades to cure illnesses and enhance health because of its improved systemic circulation and ability to regulate the drug's pharmacological action. As pharmacology and pharmacokinetics advanced, the idea of controlled release emerged, demonstrating the significance of drug release in assessing...
Read More -
Development of novel paullone-based PROTACs as anticancer agents
Proteolysis-targeting chimera (PROTACs) represents a promising modality that has gained significant attention for cancer treatment. Using PROTAC technology, we synthesized novel structurally modified paullone-based PROTACs using Cereblon (CRBN) and Von Hippel–Lindau (VHL) E3 ligands....
Read More -
Development and verification of RP-HPLC method for the quantitative determination of Decitabine in tablet dosage formulation
Decitabine is an anti-cancer chemotherapy drug. This article describes method development and method verification of Assay of Decitabine in tablet formulation. A new, precise, rapid, accurate RP-HPLC method has been developed for the estimation of Decitabine in pharmaceutical tablets dosage form. After optimization the good chromatographic separation was achieved...
Read More
Frequently asked questions
How are oligonucleotides synthesized?
Oligonucleotides can be synthesized using solid-phase (Peptides) and one pot liquid phase (enzymatic) method in the lab for milligram to multi-kilogram scale. Steps involved in solid-phase Oligo synthesis are detritylation, coupling, oxidation and capping. One-pot liquid phase oligo synthesis requires polymerase enzyme, template oligonucleotide and nucleotide triphosphate as starting materials.
How accuracy of chemical synthesis of oligonucleotides is maintained?
Accuracy of chemical synthesis of Oligonucleotides is maintained by maintaining the order of starting materials used during the synthesis process.
What are oligonucleotide drugs?
Oligonucleotide drugs help modulate the effect of a disease-causing gene by targeted degradation/activation of gene expression or gene editing. This activity may cause the disease to be controlled or cured.
How stable are the Oligos?
Oligos are stable for 6 weeks in buffer when stored at 37°C and for long-term stability is to be stored between -20°C to -80°C. During storage, oligos should not be exposed to direct sunlight or UV rays.
What is the oligo synthesis scale?
We can Synthesis 10-40-mer oligonucleotide up to 1 gram scale.
Can you incorporate a specific modification into Oligo?
We can perform all standard modifications, with or without backbone modification, for which Phosphoramidites are commercially available. We also have the capabilities of making any customized Phosphoramidite in-house.
What are the recommended storage conditions for Oligonucleotides?
For a period of 6 weeks, Oligos can be stored in T10E1 buffer at 37°C and for the long term, Oligonucleotides can be dried down and stored with or without TE buffer at -20°C.
Does Oligonucleotide have a phosphate on the 5’ or 3’ end?
Typical Oligonucleotide synthesis does not produce phosphate on the 5’ or 3’ end. On request, oligonucleotides can be synthesized with phosphate on the 5’ or 3’ end.
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market